La vendita allo scoperto per SQZ Biotechnologies dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di SQZ Biotechnologies. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

SQZ Biotechnologies (OTC:SQZB) Azioni, Report sulle vendite allo scoperto

SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.

SQZ BIOTECHNOLOGIES CO by SQZ Biotechnologies Company

SQZ Biotechnologies Co

<ul>
<li>Entering into $250 million accelerated share repurchase plan</li>
</ul>
 &nbsp;

News

Buybacks

Global Payments Board Approved A $250M Accelerated Share Buyback Plan

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and raises the price target from $68 to $71.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $71

Earnings

Earnings Misses

Hyatt Hotels Q4 2024 Adj. EPS $0.42 Misses $0.78 Estimate

Global Payments Q4 2024 Adj. EPS $2.95 Misses $2.96 Estimate, Sales $2.289B Miss $2.305B Estimate

Marui Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MAURY#OTC">MAURY</a>) reported quarterly earnings of $0.48 per share. This is a 9.09 percent increase over earnings of $0.44 per share from the same period last year. The company reported $419.03 million in sales this quarter. This is a 6.09 percent increase over sales of $394.98 million the same period last year.

MAURY

Marui Group Q3 EPS $0.48 Up From $0.44 YoY, Sales $419.03M Up From $394.98M YoY

The company is introducing 2025 adjusted EPS guidance of $6.17 to $6.42 and extending its long-term adjusted EPS growth rate of 5% to 7% through 2029 off the 2025 midpoint of $6.30. Management does not forecast reported GAAP EPS and related long-term growth rates.

Guidance

Duke Energy Sees FY2025 Adj EPS $6.17-$6.42 vs $6.33 Estimate

Canaccord Genuity analyst Austin Moeller maintains Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) with a Buy and lowers the price target from $7 to $6.5.

BIOX

Canaccord Genuity Maintains Buy on Bioceres Crop Solutions, Lowers Price Target to $6.5

Needham analyst Laura Martin reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and maintains $145 price target.

Reiteration

Needham Reiterates Buy on Trade Desk, Maintains $145 Price Target

Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) reported quarterly earnings of $1.66 per share which met the analyst consensus estimate. This is a 9.93 percent increase over earnings of $1.51 per share from the same period last year. The company reported quarterly sales of $7.36 billion which beat the analyst consensus estimate of $7.33 billion by 0.47 percent. This is a 2.05 percent increase over sales of $7.21 billion the same period last year.

Earnings Beats

Duke Energy Q4 2024 GAAP EPS $1.66, Inline, Sales $7.36B Beat $7.33B Estimate

Outlook
Our guidance for 2025 is described below:
<ul>
<li>Revenue in the range of $4.2 billion to $4.4 billion</li>
<li>Adjusted EBITDA margin in the range of 11.0% to 12.0%</li>
<li>SG&amp;A expense of approximately 9.0% of revenue, inclusive of an estimated $45 million of stock-based compensation expense</li>
<li>Mid-20s effective tax rate for adjusted net income</li>
<li>Capital expenditures of approximately $140 million to $160 million</li>
</ul>

Granite Expects 2025 Revenue Of $4.2B-$4.4B Vs. $4.255B Consensus, And Sees Adjusted EBITDA Margin Of 11% -12%

Gopi Chande, Chief Financial Officer said, "For 2025, our revenue outlook reflects the dynamics and volatility we're seeing in the industry, with strong early signs of demand across our Digital Solutions service line. Our margin expectations assume further stabilization as well as investments to support our return to organic growth."

TIXT

TELUS Digital Expects FY25 Revenue Growth Of Approximately 2% On An Organic Basis, Adjusted EPS Of $0.32 (Est $0.35)

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $298 to $265.

BIIB

Canaccord Genuity Maintains Buy on Biogen, Lowers Price Target to $265

Sally Beauty Holdings Issues Q2 Outlook: Sees Comparable Sales To Be Approximately Flat Compared To Prior Year; Adjusted Operating Margin Is Expected To Be In Range Of 8%-8.3%

Needham analyst Mike Matson reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and maintains $51 price target.

ATRC

Needham Reiterates Buy on AtriCure, Maintains $51 Price Target

TELUS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.11 by 63.64 percent. This is a 2.27 percent increase over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $3.85 billion which beat the analyst consensus estimate of $3.75 billion by 2.67 percent. This is a 0.73 percent increase over sales of $3.82 billion the same period last year.

TELUS Q4 Adj $0.18 Beats $0.11 Estimate, Sales $3.85B Beat $3.75B Estimate

Dividends

General

Brookfield Corporation Increased Its Quarterly Dividend By 13% To $0.09 Per Share, Payable On March 31, 2025 To Shareholders Of Record As At The Close Of Business On March 14, 2025

Sally Beauty Holdings Reiterates FY25 Outlook: Sees Comparable To Be Flat To Up 2% YoY; Consolidated Net Sales Are Now Expected To Be Approximately 100 Basis Points Lower Than Comparable Sales

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and raises the price target from $61 to $66.

Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $66

TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 115.38 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $691.00 million which beat the analyst consensus estimate of $672.60 million by 2.73 percent. This is a 0.14 percent decrease over sales of $692.00 million the same period last year.

TELUS Digital Q4 2024 Adj EPS $(0.04) Misses $(0.02) Estimate

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and raises the price target from $7 to $8.

Comments

SQZ Biotechnologies

Vendite allo scoperto

SQZ Biotechnologies (OTC:SQZB) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO